The NIDDK Disorders of Gastrointestinal Interoception Consortium (DGIC) - Clinical Research Centers (U01 Clinical Trial Not Allowed)

The National Institutes of Health, through the National Institute of Diabetes and Digestive and Kidney Diseases, is soliciting applications for the Disorders of Gastrointestinal Interoception Consortium (DGIC) under solicitation RFA-DK-28-213. This initiative utilizes a U01 cooperative agreement mechanism to establish up to six Clinical Research Centers (CRC) over a maximum project period of five years. The primary objectives are to identify mechanisms linking altered gastrointestinal interoception to dysmotility and symptoms, develop disease or response biomarkers for pathophysiology and treatment efficacy, and utilize advanced technologies to identify novel therapeutic targets for future clinical trials. The consortium focuses on motility disorders in both adults and children, with specific requirements for the recruitment and enrollment of human patients and the collection of biospecimens and clinical data. The total program funding is 4.5 million dollars, with individual application budgets limited to 500,000 dollars in direct costs per year. Eligible applicants must be domestic organizations with active registrations in SAM.gov, eRA Commons, and Grants.gov, as non-U.S. entities are ineligible. Evaluation is based on the importance of the research, rigor and feasibility of the approach, and the expertise of the investigators and their environment. Key submission requirements include a mandatory Consortium Assurance letter and adherence to strict cybersecurity incident reporting and human subject protection protocols. Applications must be submitted via Grants.gov by the deadline of March 5, 2027.